Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas.
about
A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphomaRadioimmunotherapy in Non-Hodgkin Lymphoma: Opinions of Nuclear Medicine Physicians and Radiation OncologistsPrediction of therapy tumor-absorbed dose estimates in I-131 radioimmunotherapy using tracer data via a mixed-model fit to time activityPredicting hematologic toxicity in patients undergoing radioimmunotherapy with 90Y-ibritumomab tiuxetan or 131I-tositumomabPhase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with 131I-tositumomab.Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas.Update on the rational use of tositumomab and iodine-131 tositumomab radioimmunotherapy for the treatment of non-Hodgkin's lymphomaMonoclonal antibodies and autologous stem cell transplantation for lymphoma.Arterial wall dosimetry for non-Hodgkin lymphoma patients treated with radioimmunotherapy.Therapeutic potential of 90Y- and 131I-labeled anti-CD20 monoclonal antibody in treating non-Hodgkin's lymphoma with pulmonary involvement: a Monte Carlo-based dosimetric analysis.Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysisEffect of platelet-derived growth factor receptor-beta inhibition with STI571 on radioimmunotherapy.Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease.Monoclonal antibodies in the treatment of malignancy: basic concepts and recent developments.Should involved-field radiation therapy be used as an adjunct to lymphoma autotransplantation?Tumor-Absorbed Dose Predicts Progression-Free Survival Following (131)I-Tositumomab RadioimmunotherapyMonoclonal antibody therapy for lymphoma: an update.Transformation of follicular lymphomaTransformed lymphoma: an Achilles' heel of non-Hodgkin's lymphoma.Treatment options for transformed lymphoma: incorporating allogeneic stem cell transplantation in a multimodality approach.Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model.Comparison of I-131 radioimmunotherapy tumor dosimetry: unit density sphere model versus patient-specific Monte Carlo calculationsRituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-hodgkin lymphoma.131I-tositumomab radioimmunotherapy: initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modelingA phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphomaA review of tositumomab and I(131) tositumomab radioimmunotherapy for the treatment of follicular lymphoma.Targeted cancer therapy using radiolabeled monoclonal antibodies.Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncologyTargeted radio-immunotherapy with Bexxar produces durable remissions in patients with late stage low grade non-Hodgkin's lymphomasLong-term complete responses after 131I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphomaCurrent results and future applications of radioimmunotherapy management of non-Hodgkin's lymphoma.Superior long-term outcome of patients with early transformation of non-Hodgkin lymphoma undergoing stem cell transplantationIodine 131 tositumomab in the treatment of non-Hodgkin's lymphoma.Radioimmunotherapy and stem-cell transplantation in the treatment of aggressive B-cell lymphoma.Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource.Targeted radionuclide therapy.Infectious complications associated with monoclonal antibodies and related small moleculesAnniversary paper: nuclear medicine: fifty years and still countingTreatment of follicular lymphoma: current status.
P2860
Q28343471-FC26BAA1-56EE-412F-A691-789D46B0B822Q29030891-A7BB8AA8-8946-42CB-BC72-81EB1B85ED2DQ30561088-C958975E-9AA4-4AB8-B852-70A1E483CD8DQ33392939-77F0268F-65C7-4475-A8A3-E2525467229DQ33414603-A52B0A27-36F0-4D66-849F-CE991F7451FBQ33781006-C072C555-B331-4F67-B62E-FFCFD75B74D9Q33915986-A7B74B81-4C45-4FCD-BE53-0DE46DF523C1Q34229700-1ED31454-5762-4924-A810-50A311761E4DQ34255798-4D1C8D88-FBB3-46D4-B119-F8BD7245D37AQ34255894-04968287-9DDB-4ABB-BD20-CCAE6CD9DF5DQ34272887-915D4780-75E5-4F9A-A7C8-30244DC4B310Q34343317-1745A45C-73E9-4039-A83A-191EF60E0CDBQ34360360-2ACC9058-40C7-4390-A170-B56AB24DAEE8Q34478304-E2E7A3B5-8746-4BB8-9D97-D11E383BAF63Q34541079-7B22791B-C6D9-4EE1-A604-F32E58FB31F0Q34543794-A003F83E-CC3D-4B7E-919A-2BA1CA60E633Q34552428-7B42754A-B648-475C-9282-BED28E607B92Q35038729-29ECAF4C-8510-48D0-BDC9-F0DA0A3CA8EFQ35106138-CCBE0A13-6438-449D-8A0A-3196104ABB31Q35166811-76654BA3-259C-48CD-A9D4-BC26B988CF7FQ35220659-13A2ED26-3F85-4F30-AEB7-74A0ABB2F856Q35288449-FFAE01DA-B6DA-4DBF-809C-6D1B7B4010F8Q35567244-5A72829A-0C38-49B3-969F-C8F1C6D15DA3Q35589582-4393707B-320E-4BEB-B0A4-AAFF91CFA457Q35825755-D978E348-34D6-432E-9B5B-665163AB41FFQ35848351-12EFF24E-8029-43C5-A577-2DD65EECD3F6Q36150468-BC1F2D42-6980-4723-8535-5C046B7D616EQ36200161-E860A6B1-8F41-452E-AC5F-E46A64DB77C1Q36339722-58E5C2EA-4C5F-4835-90D8-9F544CAEB96FQ36489856-F04EC86F-9CC3-4348-8BC1-0BDB4C0FB03AQ36614459-48B1D12A-95B3-4EBC-81C9-AA0D737C62E9Q36684500-1FDEC495-15A8-4902-A31A-9FBFD6979816Q36837765-D3705E22-7A59-49F8-81F5-07C4DDEED03AQ36839758-F1134E4A-A899-4C6B-AB45-72B05A573F50Q36950052-57F7DDB2-81A7-44FF-9309-3482A23238CAQ37132380-0A86CA5B-C9B2-4E3E-A831-93A2F604329BQ37148148-77DF2FD3-4B75-4FC9-B356-FE429DE1C089Q37156636-2B77963B-CD48-4929-B560-8482216AFCD4Q37170144-CF117060-B490-4D81-B83E-00C254EB9479Q37280915-B71EC9CD-2ACF-4573-BC70-676073F1FC80
P2860
Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Multicenter phase II study of ...... -cell non-Hodgkin's lymphomas.
@en
type
label
Multicenter phase II study of ...... -cell non-Hodgkin's lymphomas.
@en
prefLabel
Multicenter phase II study of ...... -cell non-Hodgkin's lymphomas.
@en
P2093
P1476
Multicenter phase II study of ...... -cell non-Hodgkin's lymphomas.
@en
P2093
A D Zelenetz
A Z Rohatiner
G F Tidmarsh
J A Radford
M S Kaminski
P304
P356
10.1200/JCO.2000.18.6.1316
P407
P577
2000-03-01T00:00:00Z